Thiotepa
Immune Dysregulatory Disorders
Washington University School of MedicineSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
23 Active assets in the Immune Dysregulatory Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Indapta Therapeutics, INC. | Phase 2 | BB |
LIDOCAINE Ciusss de L'Est de l'Île de Montréal | Phase 4 | BB |
Fludarabine Indapta Therapeutics, INC. | Phase 2 | BB |
Evomela Washington University School of Medicine | Phase 2 | B |
Zilovertamab Oncternal Therapeutics, Inc | Phase 3 | B |
View all 38 →
Same molecule, other indications
Thiotepa is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →